Operator
Good morning. My name is Qin, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen s Second Quarter Earnings Call and Financial Update. [Operator Instructions]
Thank you. I would now like to turn the conference over to Mr. Mike Hencke, Director, Investor Relations. Mr. Hencke, you may begin your conference.
Mike Hencke
Director of Investor Relations
Good morning, and welcome to Biogen s second quarter 2021 earnings call. Before we begin, I would encourage everyone to go to the Investors section of biogen.com to find the earnings release and related financial tables, including our GAAP financial measures and a reconciliation of the GAAP to non-GAAP financial measures that we will discuss today.
Health Care Resilience & Sustainability with Allison Arwady, MD, Cecelia L Calhoun, MD, Michelle McMurry-Heath, MD & Thomas R Frieden, MD
washingtonpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from washingtonpost.com Daily Mail and Mail on Sunday newspapers.
Tecfidera Approved in China to Treat Relapsing MS
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.
(1)
TECFIDERA was approved under the National Medical Products Administration priority review process evaluating therapies with urgent clinical needs
More than 500,000 individuals worldwide living with multiple sclerosis (MS) have been treated with TECFIDERA, which has a well-established safety and efficacy profile
Biogen s expansion in China now includes treatment options approved for relapsing MS and spinal muscular atrophy
CAMBRIDGE, Mass., April 15, 2021(Nasdaq: BIIB) today announced that China s National Medical Products Administration (NMPA) has approved TECFIDERA (dimethyl fumarate) for the treatment of relapsing multiple sclerosis (MS). First introduced in 2013, TECFIDERA has demonstrated a well-established safety and efficacy profile with more than 10 years of data from clinical trials and real-world experience.